StockVS

Lumexa Imaging Holdings, Inc. (LMRI) 股票分析

医疗保健

Lumexa Imaging Holdings, Inc.

$8.17

+$0.17 (+2.12%)

最后更新: 2026年5月26日

价格走势

分析

公司概述

Lumexa Imaging Holdings, Inc. operates as a provider of outpatient medical imaging services within the United States, offering diagnostic capabilities including magnetic resonance imaging, computed tomography, positron emission tomography, X-ray, and ultrasound. The company functions within the Healthcare sector and specifically targets the Medical Devices industry, focusing on the delivery of essential diagnostic infrastructure and services to patients. Lumexa Imaging Holdings, Inc. currently holds a market capitalization of $893.82M and generates annual revenue of $1.02B, employing a workforce of 4064 individuals. These financial figures indicate that the company operates at a mid-to-large scale within its niche, possessing significant physical assets and a substantial operational footprint, yet the market valuation suggests investors are pricing the stock based on future growth potential rather than current profitability, given the negative net income relative to its revenue base.

财务健康

Lumexa Imaging Holdings, Inc. reported a total revenue of $1.02B over the trailing twelve months, with a net income of -$47.1M and an EBITDA of $91.96M. The substantial gap between the positive EBITDA and negative net income reveals a cost structure heavily impacted by significant interest expenses or other non-operating costs that erode operating profits before reaching the bottom line. Despite the reported net loss, the company generated free cash flow of $17.88M, which provides a critical buffer for financial flexibility, allowing management to service debt obligations or fund capital expenditures without immediate reliance on external equity financing. The company's margins reflect a challenging profitability environment, with a gross margin of 15.4%, an operating margin of 1.7%, and a negative profit margin of -4.6%, indicating that while the core operations generate value, fixed costs and interest burdens are consuming a large portion of earnings. The balance sheet is heavily leveraged, evidenced by a total debt load of $962.50M compared to cash reserves of $58.83M and a debt-to-equity ratio of 164.22, suggesting the firm carries significant financial risk. Liquidity remains constrained but manageable, as the current ratio stands at 1.27, indicating that current assets slightly exceed current liabilities. Furthermore, the return on equity is -12.6% and the return on assets is 1.9%, metrics that highlight the difficulty management faces in generating returns on shareholder capital and utilizing its asset base profitably in the current fiscal period.

估值评估

The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the lack of positive earnings, while the forward P/E is 9.23, implying that the market expects earnings to turn positive in the near future to justify current price levels. The price-to-book ratio stands at 1.53, suggesting that the stock trades at a moderate premium over its book value, reflecting some level of intangible value or growth expectations despite current losses. Alternative valuation multiples provide further context, with a price-to-sales ratio of 0.87 and an EV/EBITDA of 19.55, indicating that investors are willing to pay nearly 90 cents for every dollar of sales generated. The stock's trading range over the past year has been between $7.23 and $19.45, placing the current price level somewhere within this historical band, though the specific current price is not explicitly defined in the provided data points. The beta value is listed as N/A, which limits the ability to quantify the stock's volatility relative to the broader market, though the high debt levels typically imply elevated sensitivity to interest rate changes.

Growth & Income

Lumexa Imaging Holdings, Inc. demonstrated a revenue growth rate of 7.9% year-over-year, whereas earnings growth is N/A due to the company's recent losses, indicating that top-line expansion is outpacing bottom-line profitability. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings are retained and reinvested into the business rather than distributed to shareholders. This strategy of retaining earnings is consistent with a firm that must prioritize debt reduction and operational improvements before it can consider returning capital to investors. Overall, the growth and income profile is characterized by steady top-line expansion supported by strong cash flow generation, even though the company has not yet achieved a path to consistent positive net income or dividend distribution.

同行比较

Lumexa Imaging Holdings, Inc. (LMRI) 在医疗器械行业运营。以下是其与市值最接近的同行的比较:

公司 代码 市值 市盈率
Lumexa Imaging Holdings, Inc. LMRI $784.98M N/A
Abbott Laboratories ABT $150.96B 24.3
Stryker Corporation SYK $119.99B 36.2
Medtronic plc MDT $99.63B 21.7

医疗器械行业平均市盈率为60.2倍。Lumexa Imaging Holdings, Inc.的市盈率为N/A。

本分析由AI生成,仅供参考,不构成投资建议。数据可能存在延迟或不准确。在做出投资决策之前,请务必进行自己的研究并咨询合格的财务顾问。

关于Lumexa Imaging Holdings, Inc.

Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company provides outpatient medical imaging services, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) services, as well as X-ray, ultrasound, and mammography diagnostic and screening imaging services. Lumexa Imaging Holdings, Inc. was founded in 2018 and is based in Raleigh, North Carolina.

公司简介以英文显示。

访问官网 →

关键指标

市值
$784.98M
市盈率
N/A
52周最高
$19.45
52周最低
$6.45
平均成交量
1.08M

数据由Yahoo Finance通过yfinance提供。每日更新。

公司信息

交易所
NASDAQ
国家
United States
员工数
4,064